These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 19054777)

  • 1. Transdermal testosterone may improve ovarian response to gonadotrophins in low-responder IVF patients: a randomized, clinical trial.
    Fábregues F; Peñarrubia J; Creus M; Manau D; Casals G; Carmona F; Balasch J
    Hum Reprod; 2009 Feb; 24(2):349-59. PubMed ID: 19054777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pretreatment with transdermal testosterone may improve ovarian response to gonadotrophins in poor-responder IVF patients with normal basal concentrations of FSH.
    Balasch J; Fábregues F; Peñarrubia J; Carmona F; Casamitjana R; Creus M; Manau D; Casals G; Vanrell JA
    Hum Reprod; 2006 Jul; 21(7):1884-93. PubMed ID: 16517559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transdermal testosterone pretreatment in poor responders undergoing ICSI: a randomized clinical trial.
    Bosdou JK; Venetis CA; Dafopoulos K; Zepiridis L; Chatzimeletiou K; Anifandis G; Mitsoli A; Makedos A; Messinis IE; Tarlatzis BC; Kolibianakis EM
    Hum Reprod; 2016 May; 31(5):977-85. PubMed ID: 26956551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microdose flare protocol with interrupted follicle stimulating hormone and added androgen for poor responders--an observational pilot study.
    Mitri F; Behan LA; Murphy CA; Hershko-Klement A; Casper RF; Bentov Y
    Fertil Steril; 2016 Jan; 105(1):100-5.e1-6. PubMed ID: 26496380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gonadotrophin stimulation for in vitro fertilization significantly alters the hormone milieu in follicular fluid: a comparative study between natural cycle IVF and conventional IVF.
    von Wolff M; Kollmann Z; Flück CE; Stute P; Marti U; Weiss B; Bersinger NA
    Hum Reprod; 2014 May; 29(5):1049-57. PubMed ID: 24608520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Previous cycle cancellation due to poor follicular development as a predictor of ovarian response in cycles stimulated with gonadotrophin-releasing hormone agonist-gonadotrophin treatment.
    Peñarrubia J; Fábregues F; Manau D; Creus M; Carmona F; Casamitjana R; Vanrell JA; Balasch J
    Hum Reprod; 2005 Mar; 20(3):622-8. PubMed ID: 15608035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol.
    Hohmann FP; Macklon NS; Fauser BC
    J Clin Endocrinol Metab; 2003 Jan; 88(1):166-73. PubMed ID: 12519847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Live birth rates after modified natural cycle compared with high-dose FSH stimulation using GnRH antagonists in poor responders.
    Lainas TG; Sfontouris IA; Venetis CA; Lainas GT; Zorzovilis IZ; Tarlatzis BC; Kolibianakis EM
    Hum Reprod; 2015 Oct; 30(10):2321-30. PubMed ID: 26307091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized single-blind controlled trial of letrozole as a low-cost IVF protocol in women with poor ovarian response: a preliminary report.
    Goswami SK; Das T; Chattopadhyay R; Sawhney V; Kumar J; Chaudhury K; Chakravarty BN; Kabir SN
    Hum Reprod; 2004 Sep; 19(9):2031-5. PubMed ID: 15217999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparison of GnRH antagonist fixed protocol and GnRH agonists long protocol in infertile patients with normal ovarian reserve function in their first in vitro fertilization-embryo transfer cycle].
    Yang S; Chen XN; Qiao J; Liu P; Li R; Chen GA; Ma CH
    Zhonghua Fu Chan Ke Za Zhi; 2012 Apr; 47(4):245-9. PubMed ID: 22781108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Day 5 inhibin B serum concentrations as predictors of assisted reproductive technology outcome in cycles stimulated with gonadotrophin-releasing hormone agonist-gonadotrophin treatment.
    Peñarrubia J; Balasch J; Fábregues F; Carmona F; Casamitjana R; Moreno V; Calafell JM; Vanrell JA
    Hum Reprod; 2000 Jul; 15(7):1499-504. PubMed ID: 10875856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive value of androgens and multivariate model for poor ovarian response.
    Guo J; Zhang Q; Li Y; Huang J; Wang W; Huang L; Zhao X; Yang D
    Reprod Biomed Online; 2014 Jun; 28(6):723-32. PubMed ID: 24745840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ovarian response and pregnancy outcome in poor-responder women: a randomized controlled trial on the effect of luteinizing hormone supplementation on in vitro fertilization cycles.
    Barrenetxea G; Agirregoikoa JA; Jiménez MR; de Larruzea AL; Ganzabal T; Carbonero K
    Fertil Steril; 2008 Mar; 89(3):546-53. PubMed ID: 17531989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
    Beckers NG; Macklon NS; Eijkemans MJ; Ludwig M; Felberbaum RE; Diedrich K; Bustion S; Loumaye E; Fauser BC
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effect of domestic highly purified urinary follicle stimulating hormone on outcomes of in vitro fertilization-embryo transfer in controlled ovarian stimulation].
    Ye H; Huang GN; Cao YX; Zhong Y; Huang YH; Zhu GJ; Zhou LM; Chen ZJ; Shi JZ; Zeng Y; Weng N; Huang XF; Yang J; Zhu YM; Li YP; Yi D; Zhuang GL
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):838-42. PubMed ID: 24444561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of transdermal testosterone in poor responders undergoing IVF: systematic review and meta-analysis.
    González-Comadran M; Durán M; Solà I; Fábregues F; Carreras R; Checa MA
    Reprod Biomed Online; 2012 Nov; 25(5):450-9. PubMed ID: 22999555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial.
    Vuong TN; Phung HT; Ho MT
    Hum Reprod; 2015 May; 30(5):1188-95. PubMed ID: 25740882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of transdermal testosterone application on the ovarian response to FSH in poor responders undergoing assisted reproduction technique--a prospective, randomized, double-blind study.
    Massin N; Cedrin-Durnerin I; Coussieu C; Galey-Fontaine J; Wolf JP; Hugues JN
    Hum Reprod; 2006 May; 21(5):1204-11. PubMed ID: 16476678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A preliminary study on reduced dose (33 or 25 microg) gonadotropin-releasing hormone agonist long protocol for multifollicular ovarian stimulation in patients with high basal serum follicle-stimulating hormone levels undergoing in vitro fertilization-embryo transfer.
    Ku SY; Choi YS; Jee BC; Suh CS; Choi YM; Kim JG; Moon SY; Kim SH
    Gynecol Endocrinol; 2005 Oct; 21(4):227-31. PubMed ID: 16316845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does metformin affect the ovarian response to gonadotropins for in vitro fertilization treatment in patients with polycystic ovary syndrome and reduced ovarian reserve? A randomized controlled trial.
    Palomba S; Falbo A; Di Cello A; Cappiello F; Tolino A; Zullo F
    Fertil Steril; 2011 Nov; 96(5):1128-33. PubMed ID: 21917254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.